TOKYO -- Beverage group Kirin Holdings is shifting focus to health and pharmaceuticals, allocating more of its medium-term growth investment for these segments than for beer and soft drinks for the first time.
Kirin will allocate close to 100 billion yen ($865 million) to the health and pharmaceuticals operations between 2022 and 2024, President and CEO Yoshinori Isozaki told Nikkei in an exclusive interview. This would be slightly over half of the 180 billion yen for such items as development and factory upgrades under a three-year plan released in February.
